Boston Scientific (BSX) to Release Earnings on Wednesday

Boston Scientific (NYSE:BSX) is projected to post its Q1 2025 quarterly earnings results before the market opens on Wednesday, April 23rd. Analysts expect the company to announce earnings of $0.67 per share and revenue of $4.57 billion for the quarter. Boston Scientific has set its Q1 2025 guidance at 0.660-0.680 EPS and its FY 2025 guidance at 2.800-2.870 EPS.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.65 by $0.05. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. On average, analysts expect Boston Scientific to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Boston Scientific Stock Down 1.6 %

Shares of Boston Scientific stock opened at $93.63 on Tuesday. Boston Scientific has a 12-month low of $66.80 and a 12-month high of $107.17. The stock has a market capitalization of $138.49 billion, a P/E ratio of 74.90, a PEG ratio of 2.79 and a beta of 0.73. The company has a quick ratio of 1.02, a current ratio of 1.08 and a debt-to-equity ratio of 0.41. The stock has a 50 day moving average price of $99.22 and a two-hundred day moving average price of $94.54.

Insider Buying and Selling at Boston Scientific

In other news, CFO Daniel J. Brennan sold 67,333 shares of the business’s stock in a transaction on Wednesday, February 19th. The stock was sold at an average price of $105.24, for a total transaction of $7,086,124.92. Following the completion of the sale, the chief financial officer now owns 225,808 shares in the company, valued at $23,764,033.92. The trade was a 22.97 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Edward J. Ludwig sold 12,000 shares of the firm’s stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $105.48, for a total value of $1,265,760.00. Following the completion of the transaction, the director now owns 24,398 shares in the company, valued at approximately $2,573,501.04. This represents a 32.97 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 133,183 shares of company stock worth $13,948,476. 0.50% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Boston Scientific

An institutional investor recently raised its position in Boston Scientific stock. Brighton Jones LLC increased its position in shares of Boston Scientific Co. (NYSE:BSX) by 0.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 27,376 shares of the medical equipment provider’s stock after acquiring an additional 226 shares during the quarter. Brighton Jones LLC’s holdings in Boston Scientific were worth $2,445,000 as of its most recent SEC filing. 89.07% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on BSX. Truist Financial decreased their price target on shares of Boston Scientific from $120.00 to $113.00 and set a “buy” rating for the company in a report on Friday, April 11th. Wells Fargo & Company increased their price objective on Boston Scientific from $100.00 to $118.00 and gave the company an “overweight” rating in a research report on Thursday, February 6th. Stifel Nicolaus boosted their target price on shares of Boston Scientific from $100.00 to $115.00 and gave the stock a “buy” rating in a research report on Thursday, February 6th. Deutsche Bank Aktiengesellschaft upgraded shares of Boston Scientific from a “hold” rating to a “buy” rating and set a $108.00 price target on the stock in a research report on Friday, January 10th. Finally, UBS Group lifted their target price on Boston Scientific from $105.00 to $130.00 and gave the stock a “buy” rating in a research report on Friday, February 7th. One investment analyst has rated the stock with a hold rating, twenty-two have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $110.22.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.